THERAPEUTIC STRATEGIES FOR THE PREVENTION AND TREATMENT OF PREECLAMPSIA

Download full text PDF
Issue: 
3
Year: 
2017

V. Reznik (1), Candidate of Medical Sciences; Professor N. Tapilskaya (1), MD; Professor S. Gaidukov (1), MD; Professor Yu. Aleksandrovich (1), MD; O. Ryazanova (1), Candidate of Medical Sciences; Professor A. Bagrov (2), MD 1-Saint Petersburg State Pediatric University 2-I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg

In conditions accompanied by an increase in the volume of circulating fluid (sodium-dependent hypertension, preeclampsia), there are elevated plasma concentrations of one of the key endogenous digitalis-like factors of marinobufagenin. Clinical trials investigate the efficacy of antibodies to digitalis-like substances in the treatment of preeclampsia.
Keywords: 
obstetrics and gynecology
preeclampsia
intrauterine growth restriction syndrome
prevention
treatment

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Glushakov R.I., Proshin S.N., Tapil'skaja N.I. Rol' tireoidnyh gormonov v reguljatsii angiogeneza, kletochnoj proliferatsii i migratsii // Geny i kletki. – 2011; 6 (4): 26–33.
  2. Proshin S.N., Glushakov R.I., Shabanov P.D. i dr. Znachenie ekspressii TLR-retseptorov dlja vybora farmakologicheskoj korrektsii patologii shejki matki i endometrija // Geny i kletki. – 2011; 6 (1): 91–7.
  3. Reznik V.A. Vazoaktivnye faktory v patogeneze preeklampsii // Arterial'naja gipertenzija. – 2006; 12 (1):22–31.
  4. Rjazanova O.V., Aleksandrovich. Ju.S., Shifman E.M. i dr. Sovremennye aspekty terapii matochnyh krovotechenij pri predlezhanii platsenty // Pediatrija. SPb. – 2016; 7 (3): 117–27.
  5. Tapil'skaja N.I., Karpeev S.A., Kuznetsova I.V. Hronicheskij endometrit – subklinicheskoe vospalitel'noe zabolevanie organov malogo taza // Ginekologija. – 2014; 16 (1): 104–9.
  6. Averina I., Tapilskaya N., Reznik V. et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia // Cellular and Molecular Biology. – 2006; 52 (8): 19-23.
  7. Bhargava S., Tyagi S. C. Nutriepigenetic regulation by folate-homocysteine-methionine axis: a review // Mol. Cell. Biochem. – 2014; 387: 55–61.
  8. Bokslag A., van Weissenbruch M., Mol B. et al. Preeclampsia; short and long-term consequences for mother and neonate // Early Hum. Dev. – 2016; 102: 47–50.
  9. Conrad K. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention // Hum. Reprod. Update. – 2016; 22 (5): 647–64.
  10. Costa M. Preeclampsia: Reflections on How to Counsel About Preventing Recurrence // J. Obstet. Gynaecol. Can. – 2015; 37 (10): 887–93.
  11. Dodd J., McLeod A., Windrim R. et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction // Cochrane Database Syst. Rev. – 2013; 7: CD006780.
  12. Fedorova O., Kashkin V., Bagrov A. et al. Interaction of digibind with endogenous cardiotonic steroids from preeclamptic placentae // J. Hypertens. – 2010; 28 (2): 361–6.
  13. Fedorova O., Kolodkin N., Agalakova N. et al. Marinobufagenin, and endogenous a-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats // Hypertension. – 2001; 37 (2): 462–6.
  14. Fedorova O., Lakatta E., Bagrov A. Differential effects of acute NaCl loading on endogenous ouabain like and marinobufagenin like ligands of the sodium pump in Dahl hypertensive rats // Circulation. – 2000; 102: 3009–14.
  15. Fedorova O., Simbirtsev A., Kolodkin N. et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension // J. Hypertens. – 2008; 26 (12): 2414–25.
  16. Ganzevoort W., Alfirevic Z., von Dadelszen P. et al. STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis // Syst Rev. – 2014; 3: 23.
  17. Gonick H., Dring Y., Vaziri N. et al. Simultaneous measurement of marinobufegenin, oubain and hypertension associated protein in various disease state // Clin. Exp. Hypertens. – 1998; 20: 617–27.
  18. Henderson J., Whitlock E., O'Conner E. et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014. Report No.: 14-05207-EF-1.
  19. Kashkin V., Fedorova O., Bagrov A. et al. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. preliminary observations and a hypothesis // Pathophysiology. – 2007; 14 (3–4): 147–51.
  20. Kell D., Kenny L. A dormant microbial component in the development of preeclampsia // Front. Med. – 2016; 3: 60.
  21. Kim C., Romero R., Chaemsaithong P. et al. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance // Am. J. Obstet. Gynecol. – 2015; 213 (4 Suppl.): 53–69.
  22. Krishna U., Bhalerao S. Placental insufficiency and fetal growth restriction // J. Obstet. Gynaecol. India. – 2011; 61 (5): 505–11.
  23. Lam G. et al. Antepartum administration of a digoxin immune Fab (Digibind®) improves renal function in patients with severe preeclampsia. Proceedings of XVI congress of International Society for the Study of Hypertension in Pregnancy. Washington DC. – 2008; 44: 60.
  24. LaMarca H., Morris C., Pettit G. et al. Marinobufagenin impairs first trimester cytotrophoblast differentiation // Placenta. – 2006; 27 (9–10): 984–8.
  25. Maharaj C., O'Toole D., Lynch T. et al. Effects and mechanisms of action of sildenafil citrate in human chorionic arteries // Reprod. Biol. Endocrinol. – 2009; 23 (7): 34.
  26. Mastrolia S., Novack L., Thachil J. et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis // Thromb. Haemost. – 2016; 116 (5): 868–78.
  27. Meher S., Duley L., Hunter K. et al. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis // Am. J. Obstet. Gynecol. – 2017; 216 (2): 121–8..
  28. Morton J., Cooke C., Davidge S. In Utero Origins of Hypertension: Mechanisms and Targets for Therapy // Physiol. Rev. – 2016; 96 (2): 549–603.
  29. Nadeau-Vallée M., Obari D., Palacios J. et al. Sterile inflammation and pregnancy complications: a review // Reproduction. – 2016; 152: 277–92.
  30. Ohkuchi A., Hirashima C., Takahashi K. et al. Prediction and prevention of hypertensive disorders of pregnancy // Hypertens. Res. – 2017; 40 (1): 5–14.
  31. Oyston C., Stanley J., Baker P. Potential targets for the treatment of preeclampsia // Expert Opin. Ther. Targets. – 2015; 19 (11): 1517–30.
  32. Roberge S., Nicolaides K., Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic reviewand meta-analysis // Am. J. Obstet. Gynecol. – 2017; 216 (2): 110–20.
  33. Rytlewski K., Olszanecki R., Lauterbach R. et al. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report // Basic Clin. Pharmacol. Toxicol. – 2006; 99 (2): 146–52.
  34. Saleh L., Danser J., van den Meiracker A. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment // Curr. Opin. Nephrol. Hypertens. – 2016; 25 (2): 94–9.
  35. Shilova V., Fedorova O., Bagrov A. et al. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries // J. Hypertens. – 2011; 29 (4): 769–76.
  36. Thejeel B., Garg A., Clark W. et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review // Am. J. Hematol. – 2016; 91 (6): 623–30.
  37. Townsend R., O'Brien P., Khalil A. Current best practice in the management of hypertensive disorders in pregnancy // Integr. Blood Press Control. – 2016; 9: 79–94.
  38. Visser S., Hermes W., Ket J. et al. Systematic review and metaanalysis on nonclassic cardiovascular biomarkers after hypertensive pregnancy disorders // Am. J. Obstet. Gynecol. – 2014; 211: 373.
  39. von Dadelszen P., Magee L. Preventing deaths due to the hypertensive disorders of pregnancy // Best Pract. Res. Clin. Obstet. Gynaecol. – 2016; 36: 83–102